Abstract. Several new drugs that are targeted towards various angiogenic factors have shown considerable potential for controlling tumor proliferation and metastases. Expression levels of the targeted genes in primary tumors and metastases should be understood to maximize the use of such drugs. The present study aimed to clarify associations between mRNA levels of cyclooxygenase 2 (COX-2) and angiogenic factors [vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8)] in primary colorectal cancer and in corresponding liver metastasis. We also compared these gene expressions of primary colorectal cancer between patients with and without liver metastasis. In 31 pairs of formalin-fixed and paraffin-embedded primary and metastatic liver tumors as well as 27 specimens of consecutive stage II patients without recurrence, mRNA was quantified by real-time reverse transcription-polymerase chain reaction following the laser capture microdissection. We found a significantly positive correlation in IL-8 between primary tumors and matched liver metastases (p=0.034, r_s=0.39) and in VEGF (p=0.0083, r_s=0.48), but not in COX-2, which was associated with both VEGF (p=0.044, r_s=0.37) and IL-8 (p=0.0004, r_s=0.64) in primary colorectal cancers. Multiple regression analysis revealed that COX-2 was independently associated with IL-8 (p<0.0001). There were no differences in mRNA levels between patients with and without liver metastasis. The mRNA levels of VEGF and IL-8 in liver metastasis can be predicted from those in primary colorectal cancer. COX-2 might exert angiogenic activity more through the IL-8, than the VEGF pathway. These angiogenic factors were sufficiently up-regulated before hematogenous metastasis. These preliminary data merit further validation studies.

Introduction

Colorectal cancer is a worldwide leading cause of cancer death (1,2). The most promising treatment for patients with colorectal cancer is curative resection, but this is sometimes impossible. Some patients with colorectal cancer constantly relapse despite curative resection (3). Molecular targeting therapy has recently been developed for advanced colorectal cancer. Various drugs targeting anti-angiogenesis have improved the survival of patients with metastatic colorectal cancer (4), because angiogenesis is essential for tumor growth (5).

Interleukin-8 (IL-8) is a pro-inflammatory chemotactic cytokine that stimulates the migration of cells including neutrophils, monocytes, lymphocytes, and fibroblasts (6-9). The angiogenic activity of IL-8 produced by monocytes and macrophages was originally demonstrated in 1992 (10). Several investigators have reported that IL-8 is also secreted by some human colorectal cancer cells. Studies have shown that the range of IL-8 expression is 45-74% in colorectal cancer (11,12). However, details of IL-8 messenger RNA (mRNA) expression in colorectal cancer and corresponding liver metastasis remain unclear.

Senger et al originally identified the vascular endothelial growth factor (VEGF), which promotes angiogenesis, in 1983 (13). Bevacizumab is a monoclonal antibody to VEGF that has improved the survival of patients with metastatic colorectal cancer when combined with other chemotherapies (4).

Cyclooxygenase (COX) is a key enzyme that is involved in the conversion of arachidonic acid to prostaglandins. The COX-2 isoform is expressed in most organs, but can be up-regulated by various factors including cytokines, growth factors and tumor promoters (14,15). Recent studies have demonstrated that COX-2 inhibitors exert angiogenic effects...
in colorectal cancer (16,17). However, the association of mRNA between COX-2 and angiogenic factors in colorectal cancer remain unclear.

Several novel drugs that are targeted towards various angiogenic factors have shown considerable potential for controlling tumor proliferation and metastasis. To maximize the effects of such drugs, correlations between expression levels of targeted genes in primary tumors and metastases should be determined. The present study examines associations between the mRNA levels of COX-2 and angiogenic factors such as VEGF and IL-8 in primary colorectal cancer and in corresponding liver metastasis. We also evaluated the association between COX-2 and angiogenic factors.

Patients and methods

Patients. We enrolled 31 patients who had undergone surgical resection for both primary colorectal cancer and liver metastasis between April 1997 and June 2005 at Tokyo Medical and Dental University Hospital. Of these, 18 and 13 had metachronous and synchronous liver metastases, respectively. The median time from primary resection to hepatectomy was 20 months. We compared mRNA expression between primary colorectal cancer and corresponding liver metastases. We also enrolled 27 patients who had undergone curative resection for stage II colorectal cancer between January 1998 and August 2001 and who had not relapsed during a median follow-up of 4.8±1.1 years. We then compared mRNA expression between the 31 patients with liver metastasis (Group 1) and the 27 stage II patients without relapse (Group 2). Patients with ulcerative colitis, Crohn’s disease, or familial adenomatous polyposis were excluded from this study, which was approved by the institutional review board of Tokyo Medical and Dental University, and all patients provided written, informed consent to participate. None of the patients had undergone prior radiotherapy or chemotherapy. Table I summarizes their clinical and histopathological data.

Laser capture microdissection. Formalin-fixed paraffin-embedded tumor tissue blocks were cut into 10-μm-thick slices, stained with nuclear fast red (American MasterTech Scientific, Lodi, CA) and then laser capture microdissection (P.A.L.M. Microlaser Technologies AG, Munich, Germany) was applied. This technique allows only tumor cells to be examined with stromal tissues removed.

RNA isolation and cDNA synthesis. After laser capture microdissection, RNA was isolated according to the proprietary procedure of Response Genetics (US patent no. 6,248,535) and then cDNA was prepared from each sample as described (18).

Quantitative reverse transcription polymerase chain reaction (RT-PCR). Genes of interest and an internal reference gene (β-actin) were quantified using fluorescence-based real-time TaqMan detection (ABI PRISM 7900 Sequence Detection System; Applied Biosystems, Foster City, CA) as described (19) and the specific mRNA amplification primers and probes were listed in Table II. The PCR mixture comprised 1,200 nmol/l of each primer, 200 nmol/l probe, 0.4 U of AmpliTaq Gold Polymerase, 200 nmol/l each of dATP,
dCTP, dGTP, dTTP, 3.5 mmol/l MgCl₂, and 1X TaqMan buffer A containing a reference dye in a final volume of 20 μl (all reagents were supplied by Perkin-Elmer Applied Biosystems). The cycling conditions comprised 50˚C for 2 min and 95˚C for 10 min followed by 46 cycles at 95˚C for 15 sec and 60˚C for 1 min. Gene expression is expressed as ratios (relative mRNA levels) between genes of interest and the internal reference ß-actin gene. All samples were amplified in triplicate.

Statistical analysis. Data were statistically analyzed using the StatView statistical package (StatView 5.0, Abacus Concepts, Inc., Berkeley, CA, USA). All data are expressed as median ± standard deviation. We compared the mRNA levels of genes of interest between primary colorectal cancer and corresponding liver metastasis using the Wilcoxon’s signed-rank test. Spearman’s rank correlation analysis determined correlations between mRNA levels of primary tumor and matched liver metastasis from 31 patients (Group 1; Fig. 2A). On the other hand, VEGF values were significantly associated between primary tumor and matched liver metastasis (Fig. 2B; p=0.0083, rs=0.482) and IL-8 (Fig. 2C, p=0.034, rs=0.39).

Correlation in mRNA expression between primary colorectal cancer and corresponding liver metastasis. The expression of COX-2 mRNA did not significantly differ between primary colorectal cancer and corresponding liver metastasis from 31 patients (Group 1; Fig. 2A). On the other hand, VEGF values were significantly associated between primary tumor and matched liver metastasis (Fig. 2B; p=0.0083, rs=0.482) and IL-8 (Fig. 2C, p=0.034, rs=0.39).

Correlation in mRNA expression between COX-2 and angiogenic factors in primary colorectal cancer. The mRNA expression of COX-2 significantly correlated with that of VEGF in primary tumors from Group 1 patients (Fig. 3A; p=0.044, rs=0.37) and IL-8 (Fig. 3B; p=0.0004, rs=0.64). Multivariate analysis revealed that IL-8 mRNA and COX-2 mRNA expression was independently associated (Table III; p<0.0001).

Comparison of mRNA levels between patients with stage II colorectal cancer without recurrence and those with colorectal cancer with liver metastasis. The mRNA levels of primary tumors in Group 1 and 2 patients were as follows: COX-2, 0.61±0.55 and 0.59±0.78; IL-8, 6.17±7.68 and 6.27±13.43.

Table II. Primer and probe sequences of analyzed genes.

<table>
<thead>
<tr>
<th>Sequences</th>
<th>Forward primer</th>
<th>Reverse primer</th>
<th>Probe</th>
</tr>
</thead>
<tbody>
<tr>
<td>COX-2</td>
<td>5'-GCTCAAAACATGATTTGTGCATT-3'</td>
<td>5'-GCTGGCCTCCTGCTATGA-3'</td>
<td>5'-(FAM)TGCCCAGCACCTCAGCATT(TAMRA)-3'</td>
</tr>
<tr>
<td>IL-8</td>
<td>5'-CAGCTCTGTGTGAAGTGCGATT-3'</td>
<td>5'-GGAAGATGTTGGAGTAGTC-3'</td>
<td>5'-(FAM)TGCACTGATCTGAAGTTGCTGAGC(TAMRA)-3'</td>
</tr>
<tr>
<td>VEGF</td>
<td>5'-AGGGTGCAAGGAGGAGGGA-3'</td>
<td>5'-TCCAGAATTCTACCTCGT-3'</td>
<td>5'-(FAM)ATGGCAGAAGGGAGGAGGGAATCA(TAMRA)-3'</td>
</tr>
<tr>
<td>ß-actin</td>
<td>5'-TGAGCGCCTACAGCCT-3'</td>
<td>5'-TCTTAAATGTCAACGGAGATT-3'</td>
<td>5'-(FAM)ACCACCACGCCGAGG(TAMRA)-3'</td>
</tr>
</tbody>
</table>
and VEGF, 4.87±1.64 and 5.50±4.50, respectively. The COX-2 (p=0.55; Fig. 4A), IL-8 (p=0.61; Fig. 4B) and VEGF (p=0.22; Fig. 4C) mRNA levels did not differ between Groups 1 and 2.

**Discussion**

The present study demonstrated positive correlations between mRNA levels of IL-8 and VEGF, but not of COX-2 in primary colorectal cancer.
colorectal cancer and corresponding liver metastases. The expression of COX-2 in primary colorectal cancer and liver metastasis has not been examined in detail. Only one immunohistochemical study has compared COX-2 expression in primary colorectal cancer and matched liver metastasis (20). That study found that immunostaining scores of COX-2 positively correlated between primary colorectal cancer and corresponding liver metastasis. Our results contradict these findings, perhaps because they semi-quantified COX-2 protein expression whereas we quantified COX-2 mRNA levels. However, another explanation could be that COX-2 mRNA expression is more dependent on the surrounding environment under conditions of liver metastasis. Further study is required to clarify this issue. Kuramochi et al found a positive correlation in VEGF mRNA expression between primary colorectal cancer and matched liver metastasis (21). Our results support these findings.

Correlations in IL-8 mRNA levels between primary colorectal cancer and corresponding liver metastasis have not been reported. Rubie et al reported that IL-8 mRNA and protein expression is up-regulated in colorectal cancer compared with adjacent normal tissues (22). Anti-angiogenic therapy for colorectal cancer targeting IL-8 might be developed soon, and the present results should be applicable at that time.

Multiple regression analysis revealed a significant correlation between mRNA levels of IL-8 and of COX-2 in advanced colorectal cancer. To our knowledge, the association

![Figure 3. Correlation of messenger RNA expression between COX-2 and: (A), VEGF; or (B), IL-8 in primary tumors.](image)

![Figure 4. Comparison of messenger RNA expression between primary colorectal cancer with liver metastasis and stage II tumor without recurrence. (A), COX-2; (B), VEGF; and (C), IL-8.](image)
between COX-2 and IL-8 mRNA expression in colorectal cancer has not yet been reported. However, details of interactions between COX-2 and IL-8 were not clarified in the present study. Singh et al reported that COX-2 expression led to IL-8 induction in breast cancer cells (23). A similar mechanism might exist in colorectal cancer, because we found a close correlation between the mRNA levels of COX-2 and IL-8. Details of the mechanism between COX-2 and IL-8 in colorectal cancer require further investigation using various strategies.

Since Tsuji et al reported that COX-2 regulates angiogenesis in colon cancer cells (24), several studies have shown an association between COX-2 expression and angiogenesis (16,17). However, our univariate analysis found that COX-2 mRNA expression in primary colorectal cancer positively correlated with VEGF mRNA levels, whereas multivariate analysis did not. One reason for this finding might be that several factors other than COX-2 affect VEGF and thus, angiogenesis.

The present study found no differences among COX-2, VEGF, and IL-8 mRNA levels in primary colorectal cancer between patients with synchronous and metachronous liver metastases. The mRNA levels of each factor did not differ between primary tumors from patients with solitary liver or multiple liver metastases, suggesting that these genes are already sufficiently up-regulated by the time liver metastases develop from colorectal cancer. Therefore, the mRNA levels of these genes might not change with further tumor advances.

We found no difference in the IL-8 mRNA levels between TNM stage II and IV primary colorectal cancer. There were no differences in the COX-2 and VEGF mRNA levels between stages I and IV. These findings suggest that the IL-8 as well as COX-2 and VEGF mRNA levels in colorectal cancer are already sufficiently up-regulated at stage II. Anti-angiogenic therapy targeting these genes may exert their effect for patients with stage II colorectal cancer as well as for those with stage IV. To maximally exclude bias, we examined samples from consecutive patients with stage II colorectal cancer who had not developed recurrence for at least 3 years. Terada et al reported that the IL-8 levels were lower in T1, than in T2-4 stages. Therefore, IL-8 might become up-regulated early. They found higher IL-8 levels in patients with, than without liver metastases. One explanation for the difference in the results between their study and ours might be that they measured IL-8 levels using an ELISA in only 9 patients with liver metastasis. Further large-scale investigations are required to clarify this issue.

In conclusion, the present study found no association between mRNA expression of angiogenic factors and liver metastasis. The mRNA expression of these angiogenic factors in colorectal cancer might already be sufficiently up-regulated before hematogenous metastasis. The angiogenic activity of COX-2 might be exerted more through the IL-8 than the VEGF pathway. The mRNA levels of VEGF and IL-8 in liver metastasis can be predicted from those in primary colorectal cancer. These findings will be useful when considering anti-angiogenic therapy for patients with colorectal cancer, although further studies are required to validate these preliminary data.

Acknowledgments

We thank Yoko Takagi for her excellent technical assistance. Part of this study was presented at the annual AACR meeting, San Diego, April 12-16, 2008.

References


